OctoPlus announces the proposal to appoint Catherine Moukheibir to the Supervisory Board
OctoPlus N.V. announces that the Supervisory Board of the Company will nominate Catherine Moukheibir to be appointed as member of the Supervisory Board at the next General Meeting of Shareholders. This appointment will be for a period of four years.
Catherine Moukheibir MA, MBA, age 52, was CFO of Movetis, a Belgian specialty pharmaceutical company from 2008 to 2010, for which she led the IPO on Euronext Brussels and subsequently the acquisition by Shire. Previously, she was Director Capital Markets at Zeltia (from 2001 to 2007), a Spanish biopharma and consumer chemicals group, where she led financial strategy. Before joining Zeltia, she was Executive Director Investment Banking with Salomon Smith Barney and Morgan Stanley (from 1997 to 2000). Catherine Moukheibir is currently Senior Advisor Finance and member of the Executive Board of Innate Pharma S.A. and is responsible for their financial strategy.
The Supervisory Board also announces that Hans Stellingsma has informed the Board of his decision to resign from the Supervisory Board to pursue other opportunities outside the Company due to personal reasons, effectively April 15. As mentioned in a previous announcement, the Supervisory Board proposes to appoint Dr. Staf van Reet, Ph.D., as the new Chairperson of the Supervisory Board at the upcoming Annual General Meeting of Shareholders.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
